Clozapine treatment in Russia

A review of clinical research

M. Wolf, S. Wolf, William Wilson

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: This paper is intended to help American clinicians and investigators further their understanding of the clinical use of clozapine by reviewing experience with the drug in Russia, where it was introduced 17 years before it became available in the United States. Methods: Key articles on clozapine from the Russian clinical research literature were reviewed by the first two authors, former Russian clinical investigators. The third author comments briefly about the implications of this work from a contemporary American perspective. Findings and conclusions: The review found that although clozapine was not widely distributed in Russia, it was investigated at several large psychiatric research institutions and hospitals. It was not reserved for neuroleptic-resistant disorders but instead was used with some success as a first-line treatment in acute disorders. Although no controlled clinical trials were conducted, results of long-term outcome studies of treatment-resistant schizophrenia were largely in agreement with those of controlled trials and clinical follow-up studies in the U.S. The studies found short-term gains for previously refractory patients as well as improvements in social functioning that continued for extended periods in some cases. Russian investigators described clozapine as an effective antipsychotic agent that lacked the extrapyramidal side effects of other neuroleptics.

Original languageEnglish (US)
Pages (from-to)256-259
Number of pages4
JournalPsychiatric Services
Volume46
Issue number3
StatePublished - 1995

Fingerprint

Clozapine
Russia
Antipsychotic Agents
Controlled Clinical Trials
Research Personnel
schizophrenia
Research
drug
Therapeutics
Psychiatry
Schizophrenia
experience
Outcome Assessment (Health Care)
Pharmaceutical Preparations
literature

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Public Health, Environmental and Occupational Health
  • Health(social science)
  • Health Professions(all)

Cite this

Clozapine treatment in Russia : A review of clinical research. / Wolf, M.; Wolf, S.; Wilson, William.

In: Psychiatric Services, Vol. 46, No. 3, 1995, p. 256-259.

Research output: Contribution to journalArticle

Wolf, M. ; Wolf, S. ; Wilson, William. / Clozapine treatment in Russia : A review of clinical research. In: Psychiatric Services. 1995 ; Vol. 46, No. 3. pp. 256-259.
@article{1ddc17ccdb7c45b9895b80cc51439f44,
title = "Clozapine treatment in Russia: A review of clinical research",
abstract = "Objective: This paper is intended to help American clinicians and investigators further their understanding of the clinical use of clozapine by reviewing experience with the drug in Russia, where it was introduced 17 years before it became available in the United States. Methods: Key articles on clozapine from the Russian clinical research literature were reviewed by the first two authors, former Russian clinical investigators. The third author comments briefly about the implications of this work from a contemporary American perspective. Findings and conclusions: The review found that although clozapine was not widely distributed in Russia, it was investigated at several large psychiatric research institutions and hospitals. It was not reserved for neuroleptic-resistant disorders but instead was used with some success as a first-line treatment in acute disorders. Although no controlled clinical trials were conducted, results of long-term outcome studies of treatment-resistant schizophrenia were largely in agreement with those of controlled trials and clinical follow-up studies in the U.S. The studies found short-term gains for previously refractory patients as well as improvements in social functioning that continued for extended periods in some cases. Russian investigators described clozapine as an effective antipsychotic agent that lacked the extrapyramidal side effects of other neuroleptics.",
author = "M. Wolf and S. Wolf and William Wilson",
year = "1995",
language = "English (US)",
volume = "46",
pages = "256--259",
journal = "Psychiatric Services",
issn = "1075-2730",
publisher = "American Psychiatric Association",
number = "3",

}

TY - JOUR

T1 - Clozapine treatment in Russia

T2 - A review of clinical research

AU - Wolf, M.

AU - Wolf, S.

AU - Wilson, William

PY - 1995

Y1 - 1995

N2 - Objective: This paper is intended to help American clinicians and investigators further their understanding of the clinical use of clozapine by reviewing experience with the drug in Russia, where it was introduced 17 years before it became available in the United States. Methods: Key articles on clozapine from the Russian clinical research literature were reviewed by the first two authors, former Russian clinical investigators. The third author comments briefly about the implications of this work from a contemporary American perspective. Findings and conclusions: The review found that although clozapine was not widely distributed in Russia, it was investigated at several large psychiatric research institutions and hospitals. It was not reserved for neuroleptic-resistant disorders but instead was used with some success as a first-line treatment in acute disorders. Although no controlled clinical trials were conducted, results of long-term outcome studies of treatment-resistant schizophrenia were largely in agreement with those of controlled trials and clinical follow-up studies in the U.S. The studies found short-term gains for previously refractory patients as well as improvements in social functioning that continued for extended periods in some cases. Russian investigators described clozapine as an effective antipsychotic agent that lacked the extrapyramidal side effects of other neuroleptics.

AB - Objective: This paper is intended to help American clinicians and investigators further their understanding of the clinical use of clozapine by reviewing experience with the drug in Russia, where it was introduced 17 years before it became available in the United States. Methods: Key articles on clozapine from the Russian clinical research literature were reviewed by the first two authors, former Russian clinical investigators. The third author comments briefly about the implications of this work from a contemporary American perspective. Findings and conclusions: The review found that although clozapine was not widely distributed in Russia, it was investigated at several large psychiatric research institutions and hospitals. It was not reserved for neuroleptic-resistant disorders but instead was used with some success as a first-line treatment in acute disorders. Although no controlled clinical trials were conducted, results of long-term outcome studies of treatment-resistant schizophrenia were largely in agreement with those of controlled trials and clinical follow-up studies in the U.S. The studies found short-term gains for previously refractory patients as well as improvements in social functioning that continued for extended periods in some cases. Russian investigators described clozapine as an effective antipsychotic agent that lacked the extrapyramidal side effects of other neuroleptics.

UR - http://www.scopus.com/inward/record.url?scp=0028907880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028907880&partnerID=8YFLogxK

M3 - Article

VL - 46

SP - 256

EP - 259

JO - Psychiatric Services

JF - Psychiatric Services

SN - 1075-2730

IS - 3

ER -